Capricor Therapeutics (NASDAQ:CAPR) Releases Quarterly Earnings Results, Beats Expectations By $0.15 EPS

Capricor Therapeutics (NASDAQ:CAPR) released its earnings results on Wednesday. The biotechnology company reported ($0.16) EPS for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.15, Zacks reports. Capricor Therapeutics had a negative return on equity of 112.95% and a negative net margin of 146.86%.

Capricor Therapeutics Stock Up 5.3 %

NASDAQ CAPR traded up $0.61 during trading hours on Wednesday, hitting $12.22. The company had a trading volume of 1,042,031 shares, compared to its average volume of 1,364,146. Capricor Therapeutics has a fifty-two week low of $3.52 and a fifty-two week high of $23.40. The business has a fifty day simple moving average of $14.09 and a 200-day simple moving average of $14.51. The firm has a market cap of $555.64 million, a P/E ratio of -11.53 and a beta of 4.10.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a “buy” rating and set a $77.00 price objective on shares of Capricor Therapeutics in a research report on Monday. One investment analyst has rated the stock with a sell rating and six have given a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $34.50.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.